Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
14.74
-0.02 (-0.10%)
Oct 21, 2025, 10:05 AM EDT - Market open
Dr. Reddy's Laboratories Revenue
Dr. Reddy's Laboratories had revenue of 85.45B INR in the quarter ending June 30, 2025, with 11.37% growth. This brings the company's revenue in the last twelve months to 334.26B, up 15.86% year-over-year. In the fiscal year ending March 31, 2025, Dr. Reddy's Laboratories had annual revenue of 325.54B with 16.61% growth.
Revenue (ttm)
334.26B INR
Revenue Growth
+15.86%
P/S Ratio
3.12
Revenue / Employee
12,018,985 INR
Employees
27,811
Market Cap
12.15B USD
Revenue Chart
* This company reports financials in INR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 325.54B | 46.37B | 16.61% |
| Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
| Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
| Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
| Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
RDY News
- 14 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 2 months ago - Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S. - GlobeNewsWire
- 3 months ago - Dr. Reddy's Laboratories Limited (RDY) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Dr. Reddy's Q1FY26 Financial Results - Business Wire
- 3 months ago - India's Dr Reddy's to launch generic obesity drugs in 87 countries next year, CEO says - Reuters
- 4 months ago - Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug - Benzinga
- 4 months ago - Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab) - Business Wire
- 5 months ago - Dr. Reddy's Continues To Be A Good Buy At Current Valuation - Seeking Alpha